Travere Therapeutics, Inc. (TVTX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-19
Business type: Asset play
How it makes money
FILSPARI generates revenue as the only non-immunosuppressive oral drug approved to slow kidney decline for 70,000 addressable U.S. patients with primary IgAN.
FILSPARI is the primary driver of revenue, serving as a dual endothelin angiotensin receptor antagonist (DEARA). Insurance payers and specialty pharmacies pay for the treatment because it is the first medication to demonstrate a statistically significant slowing of kidney function decline compared to the standard renin-angiotensin system blockade.
Earnings are supplemented by tiered milestone payments from international partners and a passive revenue stream from the sale of the bile acid portfolio. Profitability is highly sensitive to the penetration rate within the 70,000 addressable U.S. patient population and the achievement of regulatory milestones in Europe and Japan.
What protects it: the moat
It maintains market position through two separate seven-year periods of Orphan Drug Exclusivity for FILSPARI in the U.S. granted for different IgAN indications.
Management claims Orphan Drug Exclusivity provides a robust barrier against generic competition for its lead product until at least 2031. This exclusivity covers both the reduction of proteinuria and the long-term slowing of kidney function decline in adults with primary IgAN.
The FILSPARI REMS (Risk Evaluation and Mitigation Strategy) acts as a secondary structural barrier. It mandates specific liver monitoring every three months for all patients, requiring an integrated network of certified physicians and pharmacies that is difficult for a generic competitor to replicate without a similar distribution infrastructure.
What could damage it
Generic versions of Thiola and Thiola EC already available in the market have reduced sales and could further impair revenue from the cystinuria portfolio.
Earnings are vulnerable to the rapid erosion of legacy product revenue. The entry of multiple generic versions of tiopronin tablets has already caused a decrease in net product revenues for the original and enteric-coated formulations used to treat cystinuria.
Permanent impairment could also occur if FILSPARI fails to gain traditional approval for the FSGS indication, or if competing endothelin receptor antagonists from larger rivals, such as Novartis, demonstrate superior efficacy in upcoming Phase 3 trials and displace the company's first-mover advantage.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.